Cerus Corp (CU2.DE)

5,14 0,00 (0,00%) Ab 05:35PM CEST. Markt geöffnet.

Cerus Corp

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 625

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. William M. Greenman	President, CEO & Director	970,94k	N/A	1967
Mr. Kevin D. Green	VP of Finance & CFO	569,58k	N/A	1972
Mr. Vivek K. Jayaraman	Chief Operating Officer	653,16k	N/A	1975
Ms. Chrystal Jensen	Chief Legal Officer & General Counsel	535,79k	N/A	1971
Dr. Richard J. Benjamin MBChB, Ph.D.	Chief Medical Officer	565,98k	N/A	1960
Dr. Laurence M. Corash	Co-Founder & Chief Scientific Officer	654,19k	179,81k	1944
Ms. Lori L. Roll	VP of Administration & Corporate Secretary	N/A	N/A	N/A
Mr. Matthew M. Notarianni	Senior Director of Investor Relations	N/A	N/A	N/A
Lainie Corten	Vice President of Global Marketing	N/A	N/A	N/A
Ms. Alicia Goodman	Chief Human Resources Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corps ISS Governance QualityScore, Stand 29. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 7, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.